United Therapeutics
UTHR
673 hedge funds and large institutions have $13.9B invested in United Therapeutics in 2025 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 255 increasing their positions, 230 reducing their positions, and 81 closing their positions.
11% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 81
11% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 230
1.21% more ownership
Funds ownership: 98.91% → 100.12% (+1.2%)
0% more funds holding
Funds holding: 673 → 673 (0)
3% less call options, than puts
Call options by funds: $43.4M | Put options by funds: $44.7M
11% less capital invested
Capital invested by funds: $15.6B → $13.9B (-$1.73B)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$113M |
| 2 |
DM
Deerfield Management
New York
|
+$94.3M |
| 3 |
Amundi
Paris,
France
|
+$79.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$73M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$57.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$150M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$112M |
| 3 |
Janus Henderson Group
London,
|
-$95.1M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$87.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$71.3M |
UTHR Hedge Fund Activity: Q1 2025 in Review
673 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2025, worth a combined $13.9B — down 11% from $15.6B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new UTHR positions and 81 closed out — a net gain of 9 holders — while 255 added to existing stakes and 230 trimmed.
The largest buyer was Vaughan Nelson Investment Management, opening a new position worth an estimated $113M. The largest seller was Wellington Management Group, cutting an estimated $150M.
- 673 institutional investors held United Therapeutics (UTHR) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $13.9B of United Therapeutics stock for Q1 2025, down 11% quarter-over-quarter.
- 90 funds opened new United Therapeutics positions in Q1 2025 and 81 closed out, a net change of +9 holders.
- The largest United Therapeutics buyer in Q1 2025 was Vaughan Nelson Investment Management, an estimated $113M added.
- The largest United Therapeutics seller in Q1 2025 was Wellington Management Group, an estimated $150M sold.
Based on aggregated 13F filings for Q1 2025.